Eliem Therapeutics

Youtube Subscribe

Open: 2.76 Close: 2.7 Change: -0.06

The 12 top things that an AI found about Eliem Therapeutics Company Inc... they will surprise you

The game is changing. There is a new strategy to evaluate Eliem Therapeutics fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Eliem Therapeutics are: Eliem, Therapeutics, say, isfor, strategic, alternative, include, …

Concept Map

Semantic Network

Stock Summary

Eliem Therapeutics, Inc. focuses on developing therapies for neuronal excitability disorders. Its lead drug candidate is ETX-123, a Kv7.2/3 potassium channel opener, in preclinical for the treatment of.

Today's Summary

Eliem Therapeutics says it isfor strategic alternatives, including an acquisition, merger, business combination or another transaction. The company now expects to extend the end of its cash runway from 2025 to 2027.

Today's News

Eliem Therapeutics says it isfor strategic alternatives, including an acquisition, merger, business combination or another transaction. The company now expects to extend the end of its cash runway from 2025 to 2027.

Stock Profile

"Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its lead drug candidate is ETX-123, a Kv7.2/3 potassium channel opener, which is in preclinical for the treatment of neuronal excitability disorders, such as epilepsy, pain, depression, and others; and ETX-155 for the treatment of major depressive disorder and focal onset seizures that is in Phase 2a clinical trial. The company was incorporated in 2018 and is headquartered in Redmond, Washington."

Keywords

Are looking for the most relevant information about Eliem Therapeutics? Investor spend a lot of time searching for information to make investment decisions in Eliem Therapeutics. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Eliem Therapeutics are: Eliem, Therapeutics, say, isfor, strategic, alternative, include, and the most common words in the summary are: therapeutic, inc, company, story, stock, biotech, eliem, . One of the sentences in the summary was: The company now expects to extend the end of its cash runway from 2025 to 2027.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #therapeutic #inc #company #story #stock #biotech #eliem.

Read more →

Youtube Subscribe

---